Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Fyles

Showing results (131-140 of 136) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 136 results.
Obstetrical & Gynecological Survey|December 30, 2025
Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
The Lancet. Oncology|September 8, 2025
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
Annals of Surgical Oncology|January 12, 2021
TARGIT-R (Retrospective): 5-Year Follow-Up Evaluation of Intraoperative Radiation Therapy (IORT) for Breast Cancer Performed in North AmericaStephanie A Valente, Rahul D Tendulkar, Sheen Cherian, et al.
The Lancet. Oncology|February 17, 2018
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
The Lancet. Oncology|July 27, 2019
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
International Journal of Radiation Oncology, Biology, Physics|November 1, 2020
Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
Pageof 14

Showing results (131-140 of 136) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 136 results.
Obstetrical & Gynecological Survey|December 30, 2025
Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
The Lancet. Oncology|September 8, 2025
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
Annals of Surgical Oncology|January 12, 2021
TARGIT-R (Retrospective): 5-Year Follow-Up Evaluation of Intraoperative Radiation Therapy (IORT) for Breast Cancer Performed in North AmericaStephanie A Valente, Rahul D Tendulkar, Sheen Cherian, et al.
The Lancet. Oncology|February 17, 2018
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
The Lancet. Oncology|July 27, 2019
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
International Journal of Radiation Oncology, Biology, Physics|November 1, 2020
Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
Pageof 14